Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS
Phase 1/2 Withdrawn
Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer
Phase 1/2 Withdrawn
Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer
Phase 1/2 Withdrawn
A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer
Phase 1/2 Withdrawn
Testing of the Addition of a New Anti-cancer Drug, Molibresib, to Chemotherapy Treatment (Etoposide and Cisplatin) for Patients With NUT Carcinoma
Phase 1/2 Withdrawn
MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma
Phase 1/2 Withdrawn
[18]F-Fluciclatide for Kidney Cancer Imaging Studies and Treatment
Phase 1/2 Withdrawn
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing Human Thyroglobulin to People With Thyroglobulin Expressing Thyroid Cancer
Phase 1/2 Withdrawn
Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple Myeloma
Phase 1/2 Withdrawn
Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas
Phase 1/2 Withdrawn
Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery
Phase 1/2 Withdrawn
Se-Methyl-Seleno-L-Cysteine, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment
Phase 1/2 Withdrawn
Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Phase 1/2 Withdrawn
Homoharringtonine in Treating Patients With Refractory Acute Promyelocytic Leukemia
Phase 1/2 Withdrawn
Clonidine for Neurocognitive Sequelae
Phase 1/2 Withdrawn